Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer

Mutlu H., Büyükçelik A., Akça Z., Erden A.

Journal of Oncology Pharmacy Practice, vol.21, no.1, pp.72-73, 2015 (Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 21 Issue: 1
  • Publication Date: 2015
  • Doi Number: 10.1177/1078155213508442
  • Journal Name: Journal of Oncology Pharmacy Practice
  • Journal Indexes: Scopus
  • Page Numbers: pp.72-73
  • Keywords: adverse event, breast cancer, Capecitabine, lapatinib, speech
  • Gazi University Affiliated: No

Abstract

© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.Capecitabine plus lapatinib combination is an effective chemotherapy regimen in patients with advanced breast cancer. Neurological adverse effects secondary to this regimen were reported rarely in literature. A woman with breast cancer presented with complaints of slurred speech while using the capecitabine and lapatinib combination. Her major complaint was slurred speech. No other radiologic or laboratory disorders were detected in the patient. Slurred speech improved one week after the capecitabine and lapatinib combination was discontinued without any further intervention.